A prospective study of the separate predictive capabilities of 18[F]-FDG-PET and molecular response in patients with relapsed indolent non-Hodgkin's lymphoma following treatment with iodine-131-rituximab radio-immunotherapy

Haematologica. 2008 May;93(5):789-90. doi: 10.3324/haematol.12253.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Multicenter Study

MeSH terms

  • Adult
  • Aged
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents / therapeutic use
  • Fluorodeoxyglucose F18 / pharmacology*
  • Humans
  • Iodine Radioisotopes / pharmacology*
  • Lymphoma, Non-Hodgkin / therapy*
  • Middle Aged
  • Positron-Emission Tomography / methods*
  • Predictive Value of Tests
  • Prospective Studies
  • Radioimmunotherapy / methods*
  • Remission Induction
  • Rituximab
  • Time Factors
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents
  • Iodine Radioisotopes
  • Fluorodeoxyglucose F18
  • Rituximab